Lilly Writes Three Checks in One Morning

On May 26, 2026, Eli Lilly announced it is acquiring Curevo for up to $1.5 billion, LimmaTech Biologics for up to $780 million, and Vaccine Company for up to $1.55 billion — all in cash, all announced simultaneously, according to Lilly's official press release via PR Newswire.

Total bill: up to $3.8 billion. Before lunch.

According to BioSpace, this brings Lilly's total M&A spending in 2026 alone to nearly $21 billion across six acquisitions.

What They're Actually Buying

Each deal targets a different gap in the infectious disease landscape.

Curevo is developing amezosvatein, a shingles vaccine designed to beat GSK's Shingrix on tolerability. Shingrix is a major product — GSK booked $4.8 billion in Shingrix sales in 2025, according to BioSpace. Lilly's pitch is that Shingrix's side effects — fatigue, chills, injection site pain — cause second-dose hesitancy, leaving people under-protected. Curevo's Phase 2 data, reported by PR Newswire, showed amezosvatein matched Shingrix's immune response while cutting activity-limiting side effects by more than half.

LimmaTech Biologics is working on vaccines against bacterial pathogens, including a Phase 1 candidate targeting Staphylococcus aureus, according to Fierce Biotech. The company also has candidates aimed at sexually transmitted infections like gonorrhea and chlamydia, where antibiotic resistance is becoming a serious problem. Vaccines against bacteria are notoriously hard to develop.

Vaccine Company is the most speculative of the three. They're advancing In Vivo Nanoparticle (IVN) technology — tiny particles that deliver drugs, genetic material, or diagnostic sensors directly into the body, according to CNBC. In 2024, Vaccine Company received funding from the U.S. ARPA-H — the government's high-risk health research agency — to develop vaccines against flaviviruses including Zika, dengue, and West Nile virus, per Fierce Biotech.

The Peter Marks Connection Nobody's Talking About

Months before these acquisitions, Lilly hired Peter Marks — the longtime head of FDA's Center for Biologics Evaluation and Research, the division that oversees vaccines. Marks resigned from the FDA earlier this year.

According to BioSpace, analyst firm Leerink Partners connected the dots directly: "Strategically, the trio of acquisitions is consistent with the Marks hire and signals LLY's intent to be a vaccine innovator."

Hiring the country's top vaccine regulator and then spending $3.8 billion on vaccine companies three months later speaks to Lilly's strategy. Lilly is building a vaccine division and brought in the person who wrote the regulatory rulebook to help navigate it.

The GLP-1 Cash Machine Is Funding All of This

Lilly's Zepbound and Mounjaro — its blockbuster GLP-1 weight loss and diabetes drugs — generated $4.16 billion and $4.2 billion respectively in U.S. revenue in the first quarter alone, according to CNBC. Lilly currently holds a 60.1% share of the U.S. obesity drug market, with Novo Nordisk holding 39.4%.

Lilly is using those gains to diversify before patent cliffs and competition erode the franchise. When your cash cow is printing billions per quarter, it makes sense to expand into new markets.

Lilly's chief scientific officer Daniel Skovronsky framed it as mission-driven: "These acquisitions reflect a deliberate strategy to prevent disease at its source rather than treat its consequences," according to the company's press release. Prevention markets tend to be large and sticky.

What Mainstream Coverage Is Getting Wrong

Most of the financial press is treating this as a straightforward M&A story. Buy three companies, stock ticks up 0.9%, moving on.

There are two deeper angles worth examining.

First, the antimicrobial resistance angle. LimmaTech's bacterial vaccine work isn't just interesting science — it's a response to a genuine public health crisis. Drug-resistant bacteria kill hundreds of thousands of people annually worldwide. When antibiotics stop working, vaccines become essential. Lilly is positioning itself for that future.

Second, none of these three companies had Phase 3 data in hand at the time of acquisition. Curevo's shingles vaccine is still in extended Phase 2. LimmaTech's lead candidate is in Phase 1. The Vaccine Company's IVN platform is earlier still. Lilly is paying $3.8 billion for pipelines, platforms, and potential — not proven products.

What's Next

Lilly is transforming itself from a diabetes-and-weight-loss company into something much broader. The cash is there. The strategic hire of Peter Marks gave them the regulatory expertise. Now they've bought three vaccine platforms targeting shingles, bacteria, and novel viral delivery technology.

If even one of these pays off at scale, $3.8 billion looks cheap. If all three hit clinical walls, shareholders will feel it. The vaccine business is high risk and high reward.

Regular people stand to benefit if better-tolerated shingles vaccines get more seniors vaccinated and bacterial vaccines cut antibiotic resistance.